LENSAR (LENSAR) Cash-to-Debt : 10.42 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is LENSAR Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. LENSAR's cash to debt ratio for the quarter that ended in Dec. 2023 was 10.42.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, LENSAR could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for LENSAR's Cash-to-Debt or its related term are showing as below:

LNSR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.23 Med: 9.54 Max: 10.66
Current: 10.42

During the past 5 years, LENSAR's highest Cash to Debt Ratio was 10.66. The lowest was 0.23. And the median was 9.54.

LNSR's Cash-to-Debt is ranked better than
72.82% of 861 companies
in the Medical Devices & Instruments industry
Industry Median: 1.88 vs LNSR: 10.42

LENSAR Cash-to-Debt Historical Data

The historical data trend for LENSAR's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

LENSAR Cash-to-Debt Chart

LENSAR Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.23

10.66

9.54

5.24

10.42

LENSAR Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial													5.24	2.94	9.86	10.18	10.42

Competitive Comparison of LENSAR's Cash-to-Debt

For the Medical Devices subindustry, LENSAR's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LENSAR's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LENSAR's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where LENSAR's Cash-to-Debt falls into.

LENSAR Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

LENSAR's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	24.064	/	(0.559	+	1.75)
	=	10.42

LENSAR's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	24.064	/	(0.559	+	1.75)
	=	10.42

LENSAR (NAS:LNSR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

LENSAR Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of LENSAR's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

LENSAR (LENSAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LENSAR Inc (NAS:LNSR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

2800 Discovery Drive, Orlando, FL, USA, 32826

Website

https://www.lensar.com

LENSAR Inc is a commercial-stage medical device company focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency and reproducibility by providing imaging, simplified procedure planning, efficient design and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The consumable portion of the system consists of a disposable patient interface device, or PID, kit and a procedure license. Each procedure on each system requires the use of a PID kit.

Executives

Gary M Winer	director	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Aimee S Weisner	director	ONE EDWARDS WAY, IRVINE CA 92614
Nr-gri Partners Gp, Llc	10 percent owner	867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Nr-gri Partners, Lp	10 percent owner	867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Todd B Hammer	director, 10 percent owner	NORTH RUN CAPITAL PARTNERS, 867 BOYLSTON ST., 5TH FLOOR, #1361, BOSTON MA 02116
Thomas B Ellis	director, 10 percent owner	867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
North Run Advisors, Llc	10 percent owner	62 WALNUT STREET, WELLESLEY MA 02481
North Run Capital, Lp	10 percent owner	867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Staab Thomas R Ii	officer: Chief Financial Officer	C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Kendra Wong	officer: Principal Accounting Officer	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, SUITE 100, ORLANDO FL 32826
Elizabeth G. O'farrell	director	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Alan B. Connaughton	officer: Chief Operating Officer	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Nicholas T Curtis	director, officer: Chief Executive Officer	C/O STAAR SURGICAL CO, 1911 WALKER AVE, MONROVIA CA 91016
Pdl Biopharma, Inc.	10 percent owner	59 DAMONTE RANCH PARKWAY, SUITE B-375, RENO NV 89521
Lindstrom Richard L Md	director	2811 WESTWOOD PL, WAYZATA MN 55391